Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly

A retrospective, comparative, head-to-head study

R. S. Auriemma, R. Pivonello, M. Galdiero, M. C. De Martino, M. De Leo, G. Vitale, G. Lombardi, A. Colao

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

No head-to-head comparisons are available to analyze the efficacy of octreotide (LAR) and lanreotide (LAN) as first-line treatment of acromegaly. We compared the efficacy of these two drugs in 54 newly diagnosed patients (21 women, 33 men), 27 treated with LAR (10-30 mg every 28 days) and 27 with LAN (60-90 mg/28 days), for 12 months. Each LAR-treated patient was matched with one LAN-treated patient as for GH levels, sex, and age (±5 yr). Outcome measures were GH and IGF-I levels and tumor shrinkage and secondarily classical cardiovascular risk factors (total/HDL-cholesterol ratio, glucose tolerance), blood pressure and drug tolerability. In LAR- and in LAN-treated patients, respectively: GH and IGF-I were controlled in 21 (77.7%) and in 16 patients (59.3%; p=0.26); tumor shrinkage was absent (75%) in 4 and 4 patients (p=1). The total/HDL-cholesterol ratio and insulin levels significantly decreased while glucose levels significantly increased in both groups. None of the patients with normal glucose tolerance at diagnosis developed diabetes mellitus. Side effects were mostly at the gastrointestinal level and were similar with both drugs. In conclusion, newly diagnosed patients with acromegaly treated with LAR and LAN have no significantly different prevalence of disease control, tumor shrinkage, improvement of cardiovascular risk markers and side effects. Therefore, both drugs can be safely employed as first-line therapy of acromegaly.

Original languageEnglish
Pages (from-to)956-965
Number of pages10
JournalJournal of Endocrinological Investigation
Volume31
Issue number11
Publication statusPublished - Nov 2008

Fingerprint

Octreotide
Acromegaly
Therapeutics
Insulin-Like Growth Factor I
Glucose
Pharmaceutical Preparations
HDL Cholesterol
Neoplasms
lanreotide
Diabetes Mellitus
Outcome Assessment (Health Care)
Insulin
Blood Pressure

Keywords

  • Acromegaly
  • GH
  • IGF-I
  • Lanreotide
  • Octreotide
  • Somatostatin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Auriemma, R. S., Pivonello, R., Galdiero, M., De Martino, M. C., De Leo, M., Vitale, G., ... Colao, A. (2008). Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly: A retrospective, comparative, head-to-head study. Journal of Endocrinological Investigation, 31(11), 956-965.

Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly : A retrospective, comparative, head-to-head study. / Auriemma, R. S.; Pivonello, R.; Galdiero, M.; De Martino, M. C.; De Leo, M.; Vitale, G.; Lombardi, G.; Colao, A.

In: Journal of Endocrinological Investigation, Vol. 31, No. 11, 11.2008, p. 956-965.

Research output: Contribution to journalArticle

Auriemma, RS, Pivonello, R, Galdiero, M, De Martino, MC, De Leo, M, Vitale, G, Lombardi, G & Colao, A 2008, 'Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly: A retrospective, comparative, head-to-head study', Journal of Endocrinological Investigation, vol. 31, no. 11, pp. 956-965.
Auriemma, R. S. ; Pivonello, R. ; Galdiero, M. ; De Martino, M. C. ; De Leo, M. ; Vitale, G. ; Lombardi, G. ; Colao, A. / Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly : A retrospective, comparative, head-to-head study. In: Journal of Endocrinological Investigation. 2008 ; Vol. 31, No. 11. pp. 956-965.
@article{556672baa8a84ab1bd78fdb848603c24,
title = "Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly: A retrospective, comparative, head-to-head study",
abstract = "No head-to-head comparisons are available to analyze the efficacy of octreotide (LAR) and lanreotide (LAN) as first-line treatment of acromegaly. We compared the efficacy of these two drugs in 54 newly diagnosed patients (21 women, 33 men), 27 treated with LAR (10-30 mg every 28 days) and 27 with LAN (60-90 mg/28 days), for 12 months. Each LAR-treated patient was matched with one LAN-treated patient as for GH levels, sex, and age (±5 yr). Outcome measures were GH and IGF-I levels and tumor shrinkage and secondarily classical cardiovascular risk factors (total/HDL-cholesterol ratio, glucose tolerance), blood pressure and drug tolerability. In LAR- and in LAN-treated patients, respectively: GH and IGF-I were controlled in 21 (77.7{\%}) and in 16 patients (59.3{\%}; p=0.26); tumor shrinkage was absent (75{\%}) in 4 and 4 patients (p=1). The total/HDL-cholesterol ratio and insulin levels significantly decreased while glucose levels significantly increased in both groups. None of the patients with normal glucose tolerance at diagnosis developed diabetes mellitus. Side effects were mostly at the gastrointestinal level and were similar with both drugs. In conclusion, newly diagnosed patients with acromegaly treated with LAR and LAN have no significantly different prevalence of disease control, tumor shrinkage, improvement of cardiovascular risk markers and side effects. Therefore, both drugs can be safely employed as first-line therapy of acromegaly.",
keywords = "Acromegaly, GH, IGF-I, Lanreotide, Octreotide, Somatostatin",
author = "Auriemma, {R. S.} and R. Pivonello and M. Galdiero and {De Martino}, {M. C.} and {De Leo}, M. and G. Vitale and G. Lombardi and A. Colao",
year = "2008",
month = "11",
language = "English",
volume = "31",
pages = "956--965",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "11",

}

TY - JOUR

T1 - Octreotide-LAR vs lanreotide-SR as first-line therapy for aromegaly

T2 - A retrospective, comparative, head-to-head study

AU - Auriemma, R. S.

AU - Pivonello, R.

AU - Galdiero, M.

AU - De Martino, M. C.

AU - De Leo, M.

AU - Vitale, G.

AU - Lombardi, G.

AU - Colao, A.

PY - 2008/11

Y1 - 2008/11

N2 - No head-to-head comparisons are available to analyze the efficacy of octreotide (LAR) and lanreotide (LAN) as first-line treatment of acromegaly. We compared the efficacy of these two drugs in 54 newly diagnosed patients (21 women, 33 men), 27 treated with LAR (10-30 mg every 28 days) and 27 with LAN (60-90 mg/28 days), for 12 months. Each LAR-treated patient was matched with one LAN-treated patient as for GH levels, sex, and age (±5 yr). Outcome measures were GH and IGF-I levels and tumor shrinkage and secondarily classical cardiovascular risk factors (total/HDL-cholesterol ratio, glucose tolerance), blood pressure and drug tolerability. In LAR- and in LAN-treated patients, respectively: GH and IGF-I were controlled in 21 (77.7%) and in 16 patients (59.3%; p=0.26); tumor shrinkage was absent (75%) in 4 and 4 patients (p=1). The total/HDL-cholesterol ratio and insulin levels significantly decreased while glucose levels significantly increased in both groups. None of the patients with normal glucose tolerance at diagnosis developed diabetes mellitus. Side effects were mostly at the gastrointestinal level and were similar with both drugs. In conclusion, newly diagnosed patients with acromegaly treated with LAR and LAN have no significantly different prevalence of disease control, tumor shrinkage, improvement of cardiovascular risk markers and side effects. Therefore, both drugs can be safely employed as first-line therapy of acromegaly.

AB - No head-to-head comparisons are available to analyze the efficacy of octreotide (LAR) and lanreotide (LAN) as first-line treatment of acromegaly. We compared the efficacy of these two drugs in 54 newly diagnosed patients (21 women, 33 men), 27 treated with LAR (10-30 mg every 28 days) and 27 with LAN (60-90 mg/28 days), for 12 months. Each LAR-treated patient was matched with one LAN-treated patient as for GH levels, sex, and age (±5 yr). Outcome measures were GH and IGF-I levels and tumor shrinkage and secondarily classical cardiovascular risk factors (total/HDL-cholesterol ratio, glucose tolerance), blood pressure and drug tolerability. In LAR- and in LAN-treated patients, respectively: GH and IGF-I were controlled in 21 (77.7%) and in 16 patients (59.3%; p=0.26); tumor shrinkage was absent (75%) in 4 and 4 patients (p=1). The total/HDL-cholesterol ratio and insulin levels significantly decreased while glucose levels significantly increased in both groups. None of the patients with normal glucose tolerance at diagnosis developed diabetes mellitus. Side effects were mostly at the gastrointestinal level and were similar with both drugs. In conclusion, newly diagnosed patients with acromegaly treated with LAR and LAN have no significantly different prevalence of disease control, tumor shrinkage, improvement of cardiovascular risk markers and side effects. Therefore, both drugs can be safely employed as first-line therapy of acromegaly.

KW - Acromegaly

KW - GH

KW - IGF-I

KW - Lanreotide

KW - Octreotide

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=59849111110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849111110&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 956

EP - 965

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 11

ER -